Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
LYKALABS | NSE
0.91
1.56%
Healthcare
Biotechnology
31/03/2024
21/04/2026
59.06
60.48
61.00
59.00
Lyka Labs Limited a pharmaceutical company engages in development manufacture and marketing of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations including emollient topical steroid antifungal agent topical anti-bacterial acne management dermatological formulation pain killer anti-aging cleansing lotion hair care anti-dandruff shampoo sunscreen anti-acne cosmeceutical anti-oxidant proton pump inhibitor anti-malarial anti-bacterial corticosteroid hormones cephalosporin dry powder injection muscle relaxant bone resorption inhibitor anti-oxidant/liver disease antibiotic and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities as well as technical data such as molecule stability testing data impurity profile and BA/BE clinical study data. In addition it provides products and services in therapeutic categories such as intensive care gastroenterology anti-infective anti-fungal surgery care cosmetologist urology wound care and anesthesia as well as deals in pharmaceutical products. The company offers its products in various formulations including injections creams ointments gels and lotions. It also exports its products to Bangladesh Combodia Congo Costa Rica Peru Romania Russia Sri Lanka Sudan Ukraine Venezuela and Vietnam. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai India.
View LessStrong Revenue Growth (> 10%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
50.3%1 month
92.1%3 months
60.6%6 months
50.4%813.94
-
7.79
0.86
0.37
32.54
5.16
-
154.57M
2.11B
22.48M
-
6.48
-97.10
31.60
-4.60
-
-
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
7.34
Range1M
17.89
Range3M
32.30
Rel. volume
0.10
Price X volume
576.48K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CHEMBOND | CHEMBOND | Specialty Chemicals | 148.51 | 1.96B | -1.18% | 18.24 | 1.85% |
| Tainwala Chemicals and Plastics (India) Limited | TAINWALCHM | Specialty Chemicals | 199.41 | 1.88B | -0.79% | 40.97 | 0.00% |
| Arvee Laboratories (India) Limited | ARVEE | Specialty Chemicals | 169.82 | 1.87B | 3.55% | 143.29 | 3.43% |
| Aksharchem India Ltd | AKSHARCHEM | Specialty Chemicals | 206.22 | 1.67B | -1.25% | n/a | 19.99% |
| Hindprakash Industries Limited | HPIL | Specialty Chemicals | 140.25 | 1.60B | -0.68% | 126.19 | 44.52% |
| Emmbi Industries Limited | EMMBI | Packaging & Containers | 87 | 1.55B | 0.24% | 22.75 | 91.92% |
| SIGIND | SIGIND | Specialty Chemicals | 52.92 | 1.50B | 4.56% | 16.02 | 152.53% |
| IVP Limited | IVP | Specialty Chemicals | 142.26 | 1.48B | -0.53% | 15.97 | 68.91% |
| Baid Finserv Limited | BAIDFIN | Credit Services | 11.48 | 1.38B | 3.14% | 18.38 | 145.01% |
| DCM Limited | DCM | Metal Fabrication | 71.43 | 1.35B | 0.03% | 31.60 | 8.18% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Madhav Copper Limited | MCL | Copper | 61 | 1.68B | -1.98% | 82.22 | 32.14% |
| Cubex Tubings Limited | CUBEXTUB | Copper | 93.13 | 1.35B | 1.38% | 35.85 | 21.78% |
| Touchwood Entertainment Limited | TOUCHWOOD | Advertising Agencies | 74.4 | 829.47M | -0.24% | 50.06 | 4.88% |
| Sagardeep Alloys Limited | SAGARDEEP | Copper | 24 | 416.64M | 0.50% | 58.62 | 43.14% |
| Heads UP Ventures Limited | HEADSUP | Apparel Retail | 7.21 | 157.97M | -1.10% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 32.54 | 54.00 | Cheaper |
| Ent. to Revenue | 5.16 | 7.68 | Cheaper |
| PE Ratio | 813.94 | 53.67 | Expensive |
| Price to Book | 7.79 | 6.76 | Par |
| Dividend Yield | - | 0.26 | - |
| Std. Deviation (3M) | 60.58 | 50.01 | Riskier |
| Debt to Equity | 0.86 | -0.16 | Expensive |
| Debt to Assets | 0.37 | 0.17 | Expensive |
| Market Cap | 2.11B | 129.43B | Emerging |